Paper25976012
Factor XI and contact activation as targets for antithrombotic therapy.
Gailani D and 2 others. J Thromb Haemost, 2015. Cited by 111 papers, by iCite.
Cite this record
ConductScience Library. Factor XI and contact activation as targets for antithrombotic therapy. Papers, record 25976012. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25976012
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anticoagulants | Major topic |
| Blood Coagulation | Major topic |
| Factor XI | Major topic |
| Factor XII | Major topic |
| Fibrinolytic Agents | Major topic |
| Venous Thrombosis | Major topic |
| Animals | |
| Disease Models, Animal | |
| Drug Design | |
| Enzyme Activation | |
| Hemorrhage | |
| Humans | |
| Molecular Targeted Therapy | |
| Risk Factors | |
| Treatment Outcome |
Source PubMed
Grants17
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| HL58837 | NHLBI NIH HHS | United States | R01HL058837 | PubMed and NIH | NIH RePORTER |
| HL101972 | NHLBI NIH HHS | United States | R01HL101972 | PubMed and NIH | NIH RePORTER |
| UL1TR000128 | NCATS NIH HHS | United States | UL1TR000128 | PubMed and NIH | NIH RePORTER |
| K01 RR000163 | NCRR NIH HHS | United States | P06RR000163 | PubMed and NIH | NIH RePORTER |
| RR000163 | NCRR NIH HHS | United States | P06RR000163 | PubMed and NIH | NIH RePORTER |
| AI088937 | NIAID NIH HHS | United States | R43AI088937 | PubMed and NIH | NIH RePORTER |
| R01 HL081326 | NHLBI NIH HHS | United States | R01HL081326 | PubMed and NIH | NIH RePORTER |
| UL1 TR000128 | NCATS NIH HHS | United States | UL1TR000128 | PubMed and NIH | NIH RePORTER |
| P51 RR000163 | NCRR NIH HHS | United States | P06RR000163 | PubMed and NIH | NIH RePORTER |
| R44 AI088937 | NIAID NIH HHS | United States | R43AI088937 | PubMed and NIH | NIH RePORTER |
| R43 AI088937 | NIAID NIH HHS | United States | R43AI088937 | PubMed and NIH | NIH RePORTER |
| HL81326 | NHLBI NIH HHS | United States | R01HL081326 | PubMed and NIH | NIH RePORTER |
| R01 HL058837 | NHLBI NIH HHS | United States | R01HL058837 | PubMed and NIH | NIH RePORTER |
| R01 HL101972 | NHLBI NIH HHS | United States | R01HL101972 | PubMed and NIH | NIH RePORTER |
| P40RR000163 | NIH | NIH RePORTER | |||
| P51RR000163 | NIH | NIH RePORTER | |||
| R44AI088937 | NIH | NIH RePORTER |
References91
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19617576 | Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. | Blood | 2009 | https://conductscience.org/library/papers/19617576 | PubMed |
| 2 | 21527525 | Activation of factor XI by products of prothrombin activation. | Blood | 2011 | https://conductscience.org/library/papers/21527525 | PubMed |
| 3 | 19534693 | Recent developments in thrombin-activatable fibrinolysis inhibitor research. | Mini Rev Med Chem | 2009 | https://conductscience.org/library/papers/19534693 | PubMed |
| 4 | 20798043 | Extracellular DNA traps promote thrombosis. | Proc Natl Acad Sci U S A | 2010 | https://conductscience.org/library/papers/20798043 | PubMed |
| 5 | 24018259 | Secondary prevention of venous thromboembolism. | BMJ | 2013 | https://conductscience.org/library/papers/24018259 | PubMed |
| 6 | 25696834 | Future prospects for contact factors as therapeutic targets. | Hematology Am Soc Hematol Educ Program | 2014 | https://conductscience.org/library/papers/25696834 | PubMed |
| 7 | 21828145 | Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. | Blood | 2011 | https://conductscience.org/library/papers/21828145 | PubMed |
| 8 | 25202141 | Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. | Blood | 2014 | https://conductscience.org/library/papers/25202141 | PubMed |
| 9 | 25696835 | Recent insights into the role of the contact pathway in thrombo-inflammatory disorders. | Hematology Am Soc Hematol Educ Program | 2014 | https://conductscience.org/library/papers/25696835 | PubMed |
| 10 | 20723033 | A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. | J Thromb Haemost | 2010 | https://conductscience.org/library/papers/20723033 | PubMed |
| 11 | 270705 | Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. | Proc Natl Acad Sci U S A | 1977 | https://conductscience.org/library/papers/270705 | PubMed |
| 12 | 18491973 | Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis. | J Infect Dis | 2008 | https://conductscience.org/library/papers/18491973 | PubMed |
| 13 | 12689935 | Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. | Blood | 2003 | https://conductscience.org/library/papers/12689935 | PubMed |
| 14 | 24152424 | Evidence for factor IX-independent roles for factor XIa in blood coagulation. | J Thromb Haemost | 2013 | https://conductscience.org/library/papers/24152424 | PubMed |
| 15 | 17405864 | Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. | Proc Natl Acad Sci U S A | 2007 | https://conductscience.org/library/papers/17405864 | PubMed |
| 16 | 22442348 | Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. | Blood | 2012 | https://conductscience.org/library/papers/22442348 | PubMed |
| 17 | 18217146 | Factor XIa and tissue factor activity in patients with coronary artery disease. | Thromb Haemost | 2008 | https://conductscience.org/library/papers/18217146 | PubMed |
| 18 | 24759141 | Physiologic activities of the contact activation system. | Thromb Res | 2014 | https://conductscience.org/library/papers/24759141 | PubMed |
| 19 | 10706899 | High levels of coagulation factor XI as a risk factor for venous thrombosis. | N Engl J Med | 2000 | https://conductscience.org/library/papers/10706899 | PubMed |
| 20 | 20709905 | Polyphosphate exerts differential effects on blood clotting, depending on polymer size. | Blood | 2010 | https://conductscience.org/library/papers/20709905 | PubMed |
Cited by62
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 111 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40969896 | The Discovery of a Novel Anticoagulant Mechanism: Factor XI Activation Inhibitors. | ACS Pharmacol Transl Sci | 2025 | https://conductscience.org/library/papers/40969896 | PubMed |
| 40045992 | Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Milvexian in Healthy Chinese Adults. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/40045992 | PubMed |
| 39852436 | The Role of Rotational Thromboelastometry in Early Detection of the Hemostatic Derangements in Neonates with Systemic Candida Infection. | J Fungi (Basel) | 2024 | https://conductscience.org/library/papers/39852436 | PubMed |
| 39262322 | Catheter-related deep vein thrombosis: Where are we at and where are we going? Updates and ongoing unmet clinical needs. | Eur J Clin Invest | 2025 | https://conductscience.org/library/papers/39262322 | PubMed |
| 39077577 | Abelacimab in Cancer-Associated Thrombosis: The Right Drug at the Right Time for the Right Purpose. A Comprehensive Review. | Rev Cardiovasc Med | 2023 | https://conductscience.org/library/papers/39077577 | PubMed |
| 39073551 | Therapeutic Potential of FXI Inhibitors: Hype or Hope? | Drugs | 2024 | https://conductscience.org/library/papers/39073551 | PubMed |
| 39025971 | Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participants. | Sci Rep | 2024 | https://conductscience.org/library/papers/39025971 | PubMed |
| 38779744 | Novel horizons in anticoagulation: the emerging role of factor XI inhibitors across different settings. | Haematologica | 2024 | https://conductscience.org/library/papers/38779744 | PubMed |
| 38257286 | Design, Synthesis, and Evaluation of New Hybrid Derivatives of 5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-one as Potential Dual Inhibitors of Blood Coagulation Factors Xa and XIa. | Molecules | 2024 | https://conductscience.org/library/papers/38257286 | PubMed |
| 38238638 | Brain development in newborns and infants after ECMO. | World J Pediatr | 2024 | https://conductscience.org/library/papers/38238638 | PubMed |
| 38193071 | Factors XI and XII in extracorporeal membrane oxygenation: longitudinal profile in children. | Res Pract Thromb Haemost | 2023 | https://conductscience.org/library/papers/38193071 | PubMed |
| 37970718 | Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial. | Arterioscler Thromb Vasc Biol | 2024 | https://conductscience.org/library/papers/37970718 | PubMed |
| 37568292 | Persistently High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis. | J Clin Med | 2023 | https://conductscience.org/library/papers/37568292 | PubMed |
| 37522956 | Anticoagulation in the ICU: a future for contact pathway inhibition? | Intensive Care Med | 2023 | https://conductscience.org/library/papers/37522956 | PubMed |
| 37169875 | New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022. | Eur Heart J Cardiovasc Pharmacother | 2023 | https://conductscience.org/library/papers/37169875 | PubMed |
| 37101592 | Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis. | TH Open | 2023 | https://conductscience.org/library/papers/37101592 | PubMed |
| 37063763 | Combined oral contraceptives may activate the contact system in healthy women. | Res Pract Thromb Haemost | 2023 | https://conductscience.org/library/papers/37063763 | PubMed |
| 36898159 | Fluorescent Activity-Based Probe To Image and Inhibit Factor XIa Activity in Human Plasma. | J Med Chem | 2023 | https://conductscience.org/library/papers/36898159 | PubMed |
| 36583671 | A novel mouse whole blood thrombin generation assay sensitive to FXI- and FIX-mediated amplification of coagulation. | Blood Adv | 2023 | https://conductscience.org/library/papers/36583671 | PubMed |
| 36547434 | Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease. | J Cardiovasc Dev Dis | 2022 | https://conductscience.org/library/papers/36547434 | PubMed |
Genes16
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25976012
GET https://conductscience.org/api/papers/v1/25976012/references?page=2